about
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular riskHomocysteine lowering with folic acid and B vitamins in vascular diseaseEvaluation of a web-based ECG-interpretation programme for undergraduate medical students.Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART).Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry studyPsychological mediators related to clinical outcome in cognitive behavioural therapy for coronary heart disease: A sub-analysis from the SUPRIM trial.Fifteen Challenges in Establishing a Multidisciplinary Research Program on eHealth Research in a University Setting: A Case Study.Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data.Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyManagement and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial.Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study.Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac SurgeryRationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Physical activity in patients with stable coronary heart disease: an international perspectiveDo clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study.Lessons from platelet inhibition and patient outcomes.Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy.Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet InhibiTicagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
P50
Q28220058-07EF806B-9B98-4476-BDB6-5AC1E41D38D4Q28301516-F99415DB-62CF-4F60-A80C-E00ED1579BA0Q33330205-204EE929-C2F5-490E-8223-F7B439ADF57DQ33378416-8C6C1614-287C-4550-AA3D-6C1F62B15F75Q33610120-47C88159-0BFD-476D-9E75-C48C38706456Q33685086-3FD30540-B940-4D01-82D0-5908A67EA87FQ33770660-4D0E4D8F-5B3E-47CB-B74C-FE72E4097B75Q33876971-8D6DBB05-87D0-4056-9C77-43D1B2BF485BQ33924260-16BE4784-82D4-4092-94E6-CD5AA460A6F5Q34231934-7204F117-3BBD-488B-B4B4-3B35401B0A31Q34456208-92B6B4DB-86E6-4DC1-A789-F7B0F44584A5Q34683960-8748B1A8-54CB-40C2-ABC4-8C0CCAC5FF1EQ35497118-A88D8993-BE43-4DC5-A589-F5BAF14D3EE0Q35579973-30A65F01-4CE6-4EC3-AD72-590550CD79D6Q35647278-84E3731B-34FF-47B4-9176-C0868F69B3C8Q35771209-6021E3BA-1040-4B0E-BE6F-A9F568601F63Q35978289-3EF2908F-B486-4CF3-9253-F4E8E34623C9Q35978349-B724ED54-3BAE-4380-9CAC-E8C914AAE6E0Q35978709-7BF05356-3777-494C-8E58-61D860D16871Q36621337-D440DDFA-48BD-4C5C-9F4E-7F48447AF7B5Q36836440-99882259-B9C5-4C18-8CF2-0A869D8DEB39Q36883347-BAB32990-120A-418D-9A29-885B4E16C637Q36923167-EB12DDDA-17FC-4E57-9369-3A763F9EFADBQ37057109-1FF9407F-5122-4557-B352-5D093B6B0DFFQ37076194-45FA032A-E3FD-4410-B709-AFDDD163287DQ37285421-6D3AF599-9936-4F27-B26B-3145821A355BQ37291913-A3E1C317-6621-4773-8D73-2D0E22B78673Q37851910-A1C45E2F-EB9C-4156-A55B-AF858A3E6B47Q38008144-B5854A23-3E02-4D69-9D31-0D7E18BA8D69Q38371267-0ABF2B1C-C92D-454C-9E26-F04EA0C7FADEQ38385145-A9D9EB61-6F9E-4B38-8EE4-D59C38ABE71CQ38392757-140C1FE8-5B00-4275-BCF3-79D22145CE42Q38396747-A8F80D83-F396-4D7A-9B7D-9529486EF191Q38410712-D62BB7AC-FFFD-4CB0-8508-288BF1786A06Q38419246-990E46DC-621D-4C37-B956-8C47E28F41A6Q38442214-7F4D493D-3229-4CAD-85C5-3378A9356232Q38488866-2F2485C1-9424-461E-A1F4-8A3C4FADC9BAQ38689627-3064901B-C5EE-45FB-86C8-6E73E2A545D5Q38752767-8AB07F5F-1E63-45EC-8160-2A8AAA15C510Q38813966-6A3BA1BF-9EA4-4B26-9AF6-33A87868948F
P50
description
Zweeds onderzoeker
@nl
hulumtues
@sq
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Claes Held
@ast
Claes Held
@en
Claes Held
@es
Claes Held
@ga
Claes Held
@nl
Claes Held
@sl
Claes Held
@sq
type
label
Claes Held
@ast
Claes Held
@en
Claes Held
@es
Claes Held
@ga
Claes Held
@nl
Claes Held
@sl
Claes Held
@sq
prefLabel
Claes Held
@ast
Claes Held
@en
Claes Held
@es
Claes Held
@ga
Claes Held
@nl
Claes Held
@sl
Claes Held
@sq
P106
P21
P27
P31
P496
0000-0001-9402-7404